293 related articles for article (PubMed ID: 1966804)
1. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. I. Studies on blood platelets in vitro.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1990; 2(1):21-31. PubMed ID: 1966804
[TBL] [Abstract][Full Text] [Related]
2. PAF-agonistic and -antagonistic behaviour of new synthetic ether phospholipids. II. Relationships between chemical structure and inhibition of PAF-induced human platelet activation.
Ostermann G; Hofmann B; Kertscher HP; Till U
J Lipid Mediat; 1991; 3(2):225-37. PubMed ID: 1797154
[TBL] [Abstract][Full Text] [Related]
3. Platelet-stimulating and membranolytic properties of racemic PAF-acether and analogues.
Ostermann G; Kertscher HP; Till U
Biomed Biochim Acta; 1985; 44(2):K17-23. PubMed ID: 4004829
[TBL] [Abstract][Full Text] [Related]
4. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
5. Structure-activity relationships for platelet-activating factor (PAF) and analogues reveal differences between PAF receptors on platelets and macrophages.
Stewart AG; Grigoriadis G
J Lipid Mediat; 1991 Nov; 4(3):299-308. PubMed ID: 1662547
[TBL] [Abstract][Full Text] [Related]
6. [PAF-antagonists with a phospholipid structure. 1. Phospholipids with hetero-arene head groups: synthesis, characterization and determination of the action of structural elements].
Kertscher HP; Ostermann G; Findeisen M; Limmer S; Gawrisch K
Pharmazie; 1991 Aug; 46(8):575-9. PubMed ID: 1798710
[TBL] [Abstract][Full Text] [Related]
7. Proaggregatory and inhibitory effects of 2-O-ethyl analogues of platelet-activating factor (PAF) on human and rabbit platelets.
Hofmann B; Ostermann G; Kertscher HP; Till U
Thromb Res; 1988 Feb; 49(4):415-23. PubMed ID: 3381200
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
Nagaoka J; Harada K; Kimura A; Kobayashi S; Murakami M; Yoshimura T; Yamada K; Asano O; Katayama K; Yamatsu I
Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
[TBL] [Abstract][Full Text] [Related]
9. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor.
Hwang SB; Lam MH; Alberts AW; Bugianesi RL; Chabala JC; Ponpipom MM
J Pharmacol Exp Ther; 1988 Aug; 246(2):534-41. PubMed ID: 2841449
[TBL] [Abstract][Full Text] [Related]
11. [PAF-antagonists with phospholipid structure. 2. Phospholipids with heteroarene head groups and variations of the phosphorus-nitrogen distance; synthesis, characterization and structure-activity relationships].
Kertscher HP; Ostermann G
Pharmazie; 1991 Oct; 46(10):708-11. PubMed ID: 1803385
[TBL] [Abstract][Full Text] [Related]
12. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
Komuro Y; Imanishi N; Uchida M; Morooka S
Mol Pharmacol; 1990 Sep; 38(3):378-84. PubMed ID: 2402227
[TBL] [Abstract][Full Text] [Related]
13. Effects of synthetic analogues of platelet-activating factor (PAF) on fibrinolytic activity in the rat.
Hofmann B; Meisgeier U; Kertscher P; Ostermann G
Biomed Biochim Acta; 1988; 47(10-11):S161-4. PubMed ID: 3150268
[TBL] [Abstract][Full Text] [Related]
14. Natural 1-O-alkylglycerols reduce platelet-activating factor-induced release of [3H]-serotonin in rabbit platelets.
Pédrono F; Cheminade C; Legrand AB
Prostaglandins Leukot Essent Fatty Acids; 2004 Jul; 71(1):19-23. PubMed ID: 15172680
[TBL] [Abstract][Full Text] [Related]
15. Antagonism of platelet activating factor receptor binding and stimulated phosphoinositide-specific phospholipase C in rabbit platelets.
Morrison WJ; Shukla SD
J Pharmacol Exp Ther; 1989 Sep; 250(3):831-5. PubMed ID: 2550620
[TBL] [Abstract][Full Text] [Related]
16. PAF receptor. 2. Quantitative hydrophobic contribution of the agonist's etheroxid chain.
Heymans F; Steiner E; Jouquey S; Godfroid JJ
J Lipid Mediat; 1989; 1(5):303-12. PubMed ID: 2562436
[TBL] [Abstract][Full Text] [Related]
17. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
Tahraoui L; Floch A; Mondot S; Cavero I
Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
Ring PC; Seldon PM; Barnes PJ; Giembycz MA
Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
[TBL] [Abstract][Full Text] [Related]
19. Effect of platelet agonists on the binding of platelet-activating factor to human platelets.
Burgers JA; Akkerman JW
J Lipid Mediat; 1992 Sep; 5(3):289-300. PubMed ID: 1334723
[TBL] [Abstract][Full Text] [Related]
20. Rabbit blastocysts accumulate platelet-activating factor (PAF) and lyso-PAF in vitro.
Jones MA; Kudolo GB; Harper MJ
Mol Reprod Dev; 1992 Jul; 32(3):243-50. PubMed ID: 1323306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
